Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)
China · Delayed Price · Currency is CNY 9.81
-0.15 (-1.51%)
At close: Feb 13, 2026
SHE:300009 Revenue
Anhui Anke Biotechnology (Group) had revenue of 670.40M CNY in the quarter ending September 30, 2025, with 7.70% growth. This brings the company's revenue in the last twelve months to 2.58B, down -6.81% year-over-year. In the year 2024, Anhui Anke Biotechnology (Group) had annual revenue of 2.54B, down -11.51%.
Revenue (ttm)
2.58B
Revenue Growth
-6.81%
P/S Ratio
6.35
Revenue / Employee
973.69K
Employees
2,647
Market Cap
16.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.54B | -329.71M | -11.51% |
| Dec 31, 2023 | 2.87B | 534.69M | 22.94% |
| Jan 1, 2023 | 2.33B | 162.30M | 7.48% |
| Dec 31, 2021 | 2.17B | 467.35M | 27.47% |
| Dec 31, 2020 | 1.70B | -11.11M | -0.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 26.83B |
| Tibet Cheezheng Tibetan Medicine | 2.39B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Sinocelltech Group | 1.89B |
| Inner Mongolia Furui Medical Science | 1.47B |
| Jinyu Bio-technology | 1.33B |
| BrightGene Bio-Medical Technology | 1.18B |
| Hualan Biological Vaccine | 976.44M |